By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Devices will distribute ChanTest's portfolio of ion channel and GPCR cell lines under a non-exclusive deal announced today.

As part of the deal, Molecular Devices will also sell ChanTest's cell optimization services to Molecular Devices' customers worldwide using its PatchXpress 7000A, IonWorks Quattro, IonWorks Barracuda, and FLIPR Tetra systems.

Based in Cleveland, ChanTest has more than 145 ion channel and 110 GPCR cell lines

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.